Breakthrough synapse-regenerating ALS pill moves to phase 2 human trials
Spinogenix, a clinical-stage biopharmaceutical company based in California, has developed SPG302, a unique once-a-day pill that regenerates the gaps, called synapses, between neurons to restore communication in ALS patients. Following promising results from clinical trials to evaluate the drug’s safety, the FDA has approved the company’s Investigational New Drug application, paving the way for further trials and a possible watershed moment in the treatment of the fatal disease.